Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

BMC Psychiatry

Ludovic Samalin¹  Sylvie Lancrenon⁴  Sebastien Guillaume³  Philippe Courtet³  Mocrane Abbar²  Pierre Michel Llorca¹ 

[1]CHU Clermont-Ferrand, EA 7280, Clermont-Ferrand University, Clermont-Ferrand, France

[2]Department of Adult Psychiatry, CHU Caremeau, Nîmes, France

[3]CHRU Montpellier, INSERM U1061, Montpellier University, Montpellier, France

[4]Sylia-Stat, Paris, Bourg-la-Reine, France

关键词: Treatment;    Bipolar disorder;    Schizophrenia;    Antipsychotic;    Depot formulation;    Long-acting injectable;    Guidelines;   

Others  :  1123856
DOI  :  10.1186/1471-244X-13-340

 received in 2013-08-16, accepted in 2013-12-12,  发布年份 2013

【 摘 要 】

Background

Long-acting injectable (LAI) formulations are not widely used in routine practice even though they offer advantages in terms of relapse prevention. As part of a process to improve the quality of care, the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) elaborated guidelines for the use and management of antipsychotic depots in clinical practice.

Methods

Based on a literature review, a written survey was prepared that asked about 539 options in 32 specific clinical situations concerning 3 fields: target-population, prescription and use, and specific populations. We contacted 53 national experts, 42 of whom (79%) completed the survey. The options were scored using a 9-point scale derived from the Rand Corporation and the University of California in the USA. According to the answers, a categorical rank (first-line/preferred choice, second-line/alternate choice, third-line/usually inappropriate) was assigned to each option. The first-line option was defined as a strategy rated as 7–9 (extremely appropriate) by at least 50% of the experts. The following results summarize the key recommendations from the guidelines after data analysis and interpretation of the results of the survey by the scientific committee.

Results

LAI antipsychotics are indicated in patients with schizophrenia, schizoaffective disorder, delusional disorder and bipolar disorder. LAI second-generation antipsychotics are recommended as maintenance treatment after the first episode of schizophrenia. LAI first-generation antipsychotics are not recommended in the early course of schizophrenia and are not usually appropriate in bipolar disorder. LAI antipsychotics have long been viewed as a treatment that should only be used for a small subgroup of patients with non-compliance, frequent relapses or who pose a risk to others. The panel considers that LAI antipsychotics should be considered and systematically proposed to any patients for whom maintenance antipsychotic treatment is indicated. Recommendations for medication management when switching oral antipsychotics to LAI antipsychotics are proposed. Recommendations are also given for the use of LAI in specific populations.

Conclusion

In an evidence-based clinical approach, psychiatrists, through shared decision-making, should be systematically offering to most patients that require long-term antipsychotic treatment an LAI antipsychotic as a first-line treatment.

【 授权许可】

   
2013 Llorca et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 1.

Figure 5.

【 参考文献 】

• [1]Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010, 16:306-324.
• [2]Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, Dixon LB: Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res 2011, 131:127-132.
• [3]Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
• [4]Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009, 70(Suppl 4):1-46. quiz 47–48
• [5]Adams CE, Fenton MK, Quraishi S, David AS: Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001, 179:290-299.
• [6]Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU: Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2013.
• [7]Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S: Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011, 127:83-92.
• [8]Canadian Psychiatric Association: Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005, 50:7S-57S.
• [9]Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). [http://www.ncbi.nlm.nih.gov/pubmed/20704054 webcite]
• [10]Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36:71-93.
• [11]Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M: Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 2012, 134:219-225.
• [12]Barnes TR, Shingleton-Smith A, Paton C: Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl 2009, 52:S37-S42.
• [13]Patel MX, David A: Why aren’t depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat 2011, 11:203-213.
• [14]Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B: Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000, 49:80-86.
• [15]Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006, 67:1948-1953.
• [16]Haute Autorité de Santé: Guide d’analyse de la littérature et gradation des recommandations. [http://www.has-sante.fr/portail/upload/docs/application/pdf/analiterat.pdf webcite]
• [17]Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
• [18]Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009, 166:152-163.
• [19]Haute Autorité de Santé: Elaboration de recommandations de bonne pratique. Méthode “Recommandations par consensus formalisé”. 2011. [http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodologique_cf_40_pages_2011-11-03_15-40-2_278.pdf webcite]
• [20]Samalin L, Guillarma S, Courtet P, Abbar M, Lancrenon S, Llorca PM: Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians? Compr Psychiatry 2013, 54:309-320.
• [21]Llorca PM, Courtet P, Martin P, Abbar M, Gay C, Meynard JA, Bayle F, Hamon M, Lancon C, Thibaut F, Thomas P, Lancrenon S, Guillaume S, Samalin L: Screening and management of bipolar disorders: methodology. Encephale 2010, 36(Suppl 4):S76-S85.
• [22]Llorca PM, Courtet P, Martin P, Abbar M, Gay C, Meynard JA, Bayle F, Hammon M, Lancon C, Thibaut F, Thomas P, Lancrenon S, Guillaume S, Samalin L: Screening and management of bipolar disorders: results. Encephale 2010, 36(Suppl 4):S86-S102.
• [23]Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005, Spec No.:6-22.
• [24]Alexopoulos GS, Katz IR, Reynolds CF 3rd, Carpenter D, Docherty JP: The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med 2001, Spec No Pharmacotherapy:1-86.
• [25]Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP: The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005, 11(Suppl 1):5-108. quiz 110–102
• [26]Kahn DA, Sachs GS, Printz DJ, Carpenter D, Docherty JP, Ross R: Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. J Psychiatr Pract 2000, 6:197-211.
• [27]Kane JM, Leucht S, Carpenter D, Docherty JP: The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003, 64(Suppl 12):5-19.
• [28]Fleischhacker WW: Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 2009, 52:S29-S36.
• [29]Samalin L, Nourry A, Charpeaud T, Llorca P: What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder? Nord J Psychiatry 2013.
• [30]Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A: Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry 2010, 25:220-229.
• [31]Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J: Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008, 30:2378-2386.
• [32]Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J: Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008, 23:325-331.
• [33]Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, Yook KH: Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1231-1235.
• [34]Olivares JM, Alptekin K, Azorin JM, Canas F, Dubois V, Emsley R, Gorwood P, Haddad PM, Naber D, Papageorgiou G, Roca M, Thomas P, Martinez G, Schreiner A: Psychiatrists’ awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa. Patient Prefer Adherence 2013, 7:121-132.
• [35]Samalin L, Charpeaud T, Blanc O, Heres S, Llorca P: Clinicians’ attitudes toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis 2013, 201(7):553-559.
• [36]Heres S, Hamann J, Mendel R, Wickelmaier F, Pajonk FG, Leucht S, Kissling W: Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1987-1993.
• [37]Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891.
• [38]Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM, Gurpegui M: Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Disord 2010, 127:77-83.
• [39]Hassan M, Lage MJ: Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009, 66:358-365.
• [40]Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU: Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2013, 18:53-66.
• [41]Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, Davis JM, Leucht S: Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012, 38:167-177.
• [42]Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010, 123:225-233.
• [43]Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, Limosin F, Beaufils B, Vaiva G, Verdoux H, et al.: Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General Study of Schizophrenia (CGS). Schizophr Res 2012, 134:187-194.
• [44]Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. I: analysis of cases. BMC Psychiatry 2010, 10:43.
• [45]Barnes TR: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011, 25:567-620.
• [46]Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013, 14:2-44.
• [47]Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007, 68:1751-1762.
• [48]NICE: National Institute for Health and Clinical Excellence: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Alden Press UK. edn. London: The British Psychological Society and the Royal College of Psychiatrists; 2006.
• [49]Goodwin GM: Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009, 23:346-388.
• [50]Malhi GS, Adams D, Lampe L, Paton M, O’Connor N, Newton LA, Walter G, Taylor A, Porter R, Mulder RT, Berk M: Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009, 439:27-46.
• [51]Frye MA, Ha K, Kanba S, Kato T, McElroy SL, Ozerdem A, Vazquez G, Vieta E: International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry 2011, 72:1295-1310.
• [52]Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O’Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013, 15:1-44.
• [53]Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013, 14:154-219.
• [54]Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindström E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR: Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998, 8:55-66.
• [55]Kane JM, Garcia-Ribera C: Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 2009, 52:S63-S67.
• [56]Stip E, Abdel-Baki A, Bloom D, Grignon S, Roy MA: Long-acting injectable antipsychotics: an expert opinion from the Association des Médecins Psychiatres du Quebec. Can J Psychiatry 2011, 56:367-376.
• [57]Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA: Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004, 65:120-131.
• [58]Hamann J, Mendel R, Heres S, Leucht S, Kissling W: How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? Eur Neuropsychopharmacol 2010, 20:276-279.